Loading…
Drug Shortage Compounding Patient Access Act of 2025
Legislative Progress
Introduced
September 11, 2025
Latest Action
September 11, 2025
Primary Sponsor
Diana HarshbargerRepublican(TN)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
Drug Shortage Compounding Patient Access Act of 2025 This bill relaxes certain requirements for the compounding of drugs facing shortages. Currently, subject to certain requirements, compounded drugs (i.e., drugs altered to meet patient needs) do not require Food and Drug Administration (FDA) approval. There are two general categories of compounding: (1) pharmacy compounding, wherein a licensed pharmacist or physician not registered with the FDA compounds in limited quantities for identified patients; and (2) bulk compounding, wherein an FDA-registered outsourcing facility compounds in bulk for use in medical facilities. The bill permits pharmacy compounding in limited quantities for an urgent medical need not involving a specific patient if, among other requirements, the drug appeared on the FDA’s drug shortage list within a specified period. The bill also formally waives limits on pharmacy compounding of drugs that are essentially copies of commercially available drugs if the drug appeared on the shortage list within a specified period. Separately, the bill extends the period during which an outsourcing facility may compound a drug that appeared on the shortage list to 180 days after the drug’s removal from the list. The bill also requires the FDA to publish annual updates on its evaluation of substances for inclusion on the list of bulk drug substances (i.e., active pharmaceutical ingredients) that may be used in bulk compounding of drugs not on the shortage list. Finally, manufacturers of certain drugs, including life-supporting and life-sustaining drugs, must report to the FDA certain surges in demand for such drugs.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2026 · third_quarter · Pharmacy
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act; H.R. 4409, the Fair Pharmacies for Federal Employees Act; S.3549/H.R.6837, the Fiduciary Accountability, Integrity and Reform (FAIR) Act; H.R.7148, the Consolidated Appropriations Act of 2026; Rural Health Transformation Program; Creation and Implementation of TrumpRx; Comments to FDA on RFI, "Re: Increasing Access to Nonprescription Drugs; Request for Information"; S.3822, Break up Big Medicine Act; Comments to FDA on RFT, "Re: [Docket No. FDA-2025-N-6743] - Scientific and Clinical Considerations for Testosterone Replacement Therapy (TRT) in Men with Hypogonadism"; Comments to DoL, HHS, and DoT regarding "Re: Transparency in Coverage Proposed Rule [CMS-9882-P]"; Pharmacy Shortage Areas in reference to USC-NCPA joint project Mapping Tool; H.R. 7895, the PBM Kickback Prohibition Act; Comments to FDA on their comment request "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products [FDA-2025-N-6869]"; H.R.6509/S.3794, the SAFE Drug Act; H.R.5316, the Drug Shortage Compounding Patient Access Act; H.R.8779/S.4509, the Patients Before Monopolies Act; S.3788/H.R.8269, the CLEAR LABELS Act; S.1941, the Cure Hepatitis C Act of 2025; Comments to Senate Finance "Re: Request for Information: Commonsense Policy Options to Lower Drug Prices for Patients"; H.R. 8630, the PEAT Act; Comments to HHS, ASPE on "RE: Docket No. HHS-OS-2026-0332 for Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making; H.R. 10369, Net Effective Cost Transparency and Prescription Drug Affordability Act;
Client expense: $370,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)
2026 · third_quarter · Pharmacy
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $190,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Medicare/Medicaid
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Drug Shortages SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Budget/Appropriations
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Drug Shortages SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "Main Street Pharmacy Access Act" IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC monitors HR 879/S.3794 Safe Drug Act of 2026 IPC is opposed to the HRSA 340B proposed rebate model IPC opposes HR 6509/S. 3794 Safe Drug Act of 2026. IPC opposes HR 5316 the "Drug Shortage Compounding Patient Access Act of 2025" IPC supports the Breakup Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927 IPC supports the US Department of Labor proposed rule on PBM transparency [RIN 1210-AB37]
Client expense: $30,000 · Firm income: Not reported
2026 · second_quarter · Health Issues
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Pharmacy
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Client expense: $220,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Pharmacy
H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act; H.R. 4409, the Fair Pharmacies for Federal Employees Act; S.3549/H.R.6837, the Fiduciary Accountability, Integrity and Reform (FAIR) Act; H.R.7148, the Consolidated Appropriations Act of 2026; Rural Health Transformation Program; Creation and Implementation of TrumpRx; Comments to FDA on RFI, "Re: Increasing Access to Nonprescription Drugs; Request for Information"; S.3822, Break up Big Medicine Act; Comments to FDA on RFT, "Re: [Docket No. FDA-2025-N-6743] - Scientific and Clinical Considerations for Testosterone Replacement Therapy (TRT) in Men with Hypogonadism"; Comments to DoL, HHS, and DoT regarding "Re: Transparency in Coverage Proposed Rule [CMS-9882-P]"; Pharmacy Shortage Areas in reference to USC-NCPA joint project Mapping Tool; H.R. 7895, the PBM Kickback Prohibition Act; Comments to FDA on their comment request "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products [FDA-2025-N-6869]"; H.R.6509/S.3794, the SAFE Drug Act; H.R.5316, the Drug Shortage Compounding Patient Access Act; H.R.8779/S.4509, the Patients Before Monopolies Act; S.3788/H.R.8269, the CLEAR LABELS Act; S.1941, the Cure Hepatitis C Act of 2025;
2026 · second_quarter · Health Issues
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Drug Shortages SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Pharmacy
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Drug Shortages SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Budget/Appropriations
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Pharmacy
IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middlemen Act IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "Main Street Pharmacy Access Act" IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) CMS Plan Year 2027 Medicare Drug Price Negotiation Program list of negotiated drug prices and process for negotiations. IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC is opposed to the HRSA 340B proposed rebate model IPC opposes HR 6509/S. 3794 Safe Drug Act of 2026. IPC opposes HR 5316 the "Drug Shortage Compounding Patient Access Act of 2025" IPC supports the Breakup Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927 IPC supports the US Department of Labor proposed rule on PBM transparency [RIN 1210-AB37]
Client expense: $40,000 · Firm income: Not reported
2026 · first_quarter · Pharmacy
H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act; H.R. 4409, the Fair Pharmacies for Federal Employees Act; S.3549/H.R.6837, the Fiduciary Accountability, Integrity and Reform (FAIR) Act; H.R.7148, the Consolidated Appropriations Act of 2026; Rural Health Transformation Program; Creation and Implementation of TrumpRx; Comments to FDA on RFI, "Re: Increasing Access to Nonprescription Drugs; Request for Information"; S.3822, Break up Big Medicine Act; Comments to FDA on RFT, "Re: [Docket No. FDA-2025-N-6743] - Scientific and Clinical Considerations for Testosterone Replacement Therapy (TRT) in Men with Hypogonadism"; Comments to DoL, HHS, and DoT regarding "Re: Transparency in Coverage Proposed Rule [CMS-9882-P]"; Pharmacy Shortage Areas in reference to USC-NCPA joint project Mapping Tool; H.R. 7895, the PBM Kickback Prohibition Act; Comments to FDA on their comment request "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products [FDA-2025-N-6869]";
2026 · first_quarter · Pharmacy
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
Client expense: $220,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Health Issues
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2026 Appropriations. Drug Shortages SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Budget/Appropriations
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2026 Appropriations. SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Pharmacy
Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2026 Appropriations. Drug Shortages SAFE Drugs Act HR 6509/S.3794 The Drug Shortage Compounding Patient Access Act HR 5316 FY27 Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances Discussions concerning proposed legislation related to access to compounded drugs and drug shortages H.R.5316 - Drug Shortage Compounding Patient Access Act of 2025 H.R.4605 - End Prescription Drug Ads Now Act H.R.238 - Healthy Technology Act of 2025 S.5040 - Protecting Patients from Deceptive Drug Ads Online Act S.2068 - End Prescription Drug Ads Now Act
Client expense: $330,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Pharmacy
H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act;
2025 · fourth_quarter · Pharmacy
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Client expense: $140,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Health Issues
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Pharmacy
H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities;
Client expense: $340,000 · Firm income: Not reported
2025 · third_quarter · Health Issues
Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances Discussions concerning proposed legislation related to access to compounded drugs and drug shortages H.R.5316 - Drug Shortage Compounding Patient Access Act of 2025 H.R.4605 - End Prescription Drug Ads Now Act H.R.238 - Healthy Technology Act of 2025 S.5040 - Protecting Patients from Deceptive Drug Ads Online Act S.2068 - End Prescription Drug Ads Now Act
Client expense: $320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances Discussions concerning proposed legislation related to access to compounded drugs and drug shortages H.R.5316 - Drug Shortage Compounding Patient Access Act of 2025 H.R.4605 - End Prescription Drug Ads Now Act H.R.238 - Healthy Technology Act of 2025 S.5040 - Protecting Patients from Deceptive Drug Ads Online Act S.2068 - End Prescription Drug Ads Now Act
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Pharmacy
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Client expense: $140,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Health Issues
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Medicare/Medicaid
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - the Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE, White House Office
Client expense: $270,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE, White House Office
Client expense: $320,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Client expense: $230,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE